Telesta Therapeutics (TSE:TST) Receiving Somewhat Favorable News Coverage, Analysis Finds

Press coverage about Telesta Therapeutics (TSE:TST) has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Telesta Therapeutics earned a news sentiment score of 1.63 on their scale. InfoTrie also gave media headlines about the biotechnology company an news buzz score of 8 out of 10, indicating that recent media coverage is very likely to have an impact on the stock’s share price in the near future.

Telesta Therapeutics has a twelve month low of C$0.69 and a twelve month high of C$0.14.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Riverton Roll and is the property of of Riverton Roll. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://rivertonroll.com/news/2019/06/14/telesta-therapeutics-tsetst-receiving-somewhat-favorable-news-coverage-analysis-finds.html.

Telesta Therapeutics Company Profile

Telesta Therapeutics Inc is a human therapeutics company. The Company is a biotechnology company, which is focused on the licensing/acquisition and development of transformational therapeutics for the treatment of human diseases, such as cancer, immune diseases and targeted rare diseases. The Company focuses on developing drug candidate, Mycobacterium phlei cell wall-nucleic acid complex (MCNA) for the treatment of non-muscle invasive bladder cancer.

Featured Story: Beta

Receive News & Ratings for Telesta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telesta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.